HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 281, Issue 47, 35922-35930, November 24, 2006

This Article Abstract Full Text (PDF) All Versions of this Article: 281/47/35922    most recent M606577200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hatanaka, T. Articles by Setou, M. Search for Related Content PubMed PubMed Citation Articles by Hatanaka, T. Articles by Setou, M. Social Bookmarking                      What's this?

Regulation of Amino Acid Transporter ATA2 by Ubiquitin Ligase Nedd4-2^*

Takahiro Hatanaka, Yasue Hatanaka, and Mitsutoshi Setou^¶1

From the Mitsubishi Kagaku Institute of Life Sciences, 11 Minamiooya, Machida, Tokyo 194-8511, Japan, PRESTO, Japan Science and Technology Agency, 4-1-8 Honcho Kawaguchi, Saitama 332-0012, Japan, and ^¶National Institute of Physiological Sciences, 5-1 Higashiyama, Myodaiji-cho, Okazaki, Aichi 444-8787, Japan

Received for publication, July 11, 2006

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
We report here that ubiquitin ligase Nedd4-2 regulates amino acid transporter ATA2 activity on the cell surface. We first found that a proteasome inhibitor MG132 increased the uptake of -(methylamino)isobutyric acid, a model substrate for amino acid transport system A, in 3T3-L1 adipocytes as well as the preadipocytes. Transient expression of Nedd4-2 in Xenopus oocytes and Chinese hamster ovary cells down-regulated the ATA2 transport activity induced by injected cRNA and transfected cDNA, respectively. Neither the Nedd4-2 mutant with defective catalytic domain nor c-Cbl affected the ATA2 activity significantly. RNA-mediated interference of Nedd4-2 increased the ATA2 activity in the cells, and this was associated with decreased polyubiquitination of ATA2 on the cell surface membrane. Immunofluorescent analysis of Nedd4-2 in the adipocytes stably transfected with the enhanced green fluorescent protein (EGFP)-tagged ATA2 showed the co-localization of Nedd4-2 and EGFP-ATA2 in the plasma membrane but not in the perinuclear ATA2 storage site, supporting the idea that the primary site for the ubiquitination of ATA2 is the plasma membrane. These data suggest that ATA2 on the plasma membrane is subject to polyubiquitination by Nedd4-2 with consequent endocytotic sequestration and proteasomal degradation and that this process is an important determinant of the density of ATA2 functioning on the cell surface.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Amino acid transport system A is a Na⁺-dependent active transport system for neutral amino acids expressed in most tissues (1). A unique characteristic of this system is its ability to recognize N-alkylated amino acids as substrates (2). -(Methylamino)isobutyric acid (MeAIB)² is commonly used as a model substrate for system A. Among the various amino acid transport systems known to function in mammalian cells, system A is best known for its regulation (3-5). Recently, several groups including us have established the molecular identity of the amino acid transport system A (6-13). These studies have identified three distinct transporter proteins that are responsible for system A transport activity in mammalian cells, and all three transporters are capable of mediating the Na⁺-coupled uptake of the system A model substrate MeAIB. The three transporters are known as amino acid transporter A (ATA)1 (also known as SNAT1), ATA2 (SNAT2), and ATA3 (SNAT4). These transporters belong to the solute-linked carrier family SLC38 (14). ATA1 and ATA2 possess similar functional characteristics but show distinct tissue expression pattern. ATA1 is expressed primarily in the placenta and brain, whereas ATA2 is expressed ubiquitously in mammalian tissues. ATA3 is functionally distinguishable from ATA1 and ATA2, and its expression is restricted to the liver. It is generally believed that ATA2 represents system A, which is known for its regulatory features. There is also evidence to indicate that ATA2 corresponds to system A activity in adipocytes (15, 16). Recently, we reported the regulation of ATA2 in adipocytes by insulin and in diabetes.³ In detail, we showed that insulin accelerated the translocation of ATA2 from the trans-Golgi network storage site to the plasma membrane and that the steady-state levels of ATA2 mRNA decreased in diabetes. The insulin-modulated translocation does not occur via a common endosomal pathway that is available for other plasma membrane proteins but via a pathway that is specific for ATA2. It is the balance between insertion into and sequestration from the plasma membrane that determines the density of the transporter on the cell surface that is responsible for measurable transport function. Very little is known at this time on the molecular events involved in the degradation of ATA2 subsequent to sequestration from the plasma membrane.

Membrane proteins are frequently degraded in lysosomes, but there are some examples of transporter proteins being degraded by the ubiquitin-proteasome system (18-20). The ubiquitin-proteasome system is responsible for the disposal of many short-lived proteins in eukaryotic cells, and the process is initiated by covalent tagging of the target protein with a polyubiquitin chain on the lysine residue (21).

Here, we investigated the internalization and degradation pathway of ATA2 in 3T3-L1 adipocytes as well as preadipocytes. These studies show that an E3 ubiquitin ligase Nedd4-2 ligates ATA2 with the ubiquitin chain as the sorting signal for endocytosis, and then the ubiquitin-conjugated ATA2 is degraded by proteasomes. This is rather a specific internalization and degradation pathway for this membrane transporter than a general bulk pathway such as the lysosomal degradation.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Materials—Mouse ATA2 (mATA2) cDNA was cloned from mouse kidney cDNA library as described previously.³ 3T3-L1 murine fibroblasts were from Health Science Research Resources Bank (Osaka, Japan). CHO-K1 cells were provided from Cell Resource Center for Biomedical Research, Tohoku University (Sendai, Japan). Mouse Nedd4-2 cDNA, cell culture media, Lipofectamine 2000, and Alexa568-conjugated secondary antibodies were purchased from Invitrogen. [¹⁴C]MeAIB was from American Radiolabeled Chemicals (St. Louis, MO). 2-Deoxy-D-[¹⁴C]glucose (¹⁴C-labeled 2DG) was purchased from Moravek Biochemicals (Brea, CA). MG132 was purchased from the Peptide Institute Inc. (Osaka, Japan). The anti-GFP monoclonal antibody (JL-8) and the polyclonal antibodies against Nedd4 and c-Cbl were obtained from BD Biosciences (San Jose, CA). The anti-ubiquitin monoclonal antibody (1B3) was purchased from Medical Biological Laboratories (Nagoya, Japan). The horseradish peroxidase-conjugated secondary goat anti-rabbit IgG antibody was from Jackson ImmunoResearch (West Grove, PA). Mouse Nedd4 cDNA was purchased from DNAform (Ibaragi, Japan).

Cell Culture—3T3-L1 fibroblasts (preadipocytes) were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% calf serum, and differentiation was induced according to established protocols as described previously (22, 23).³ Briefly, cells were allowed to reach confluence at least 2 days before the induction of differentiation. Differentiation was induced (on day 0) with high glucose DMEM, 10% fetal bovine serum containing 0.25 µM dexamethasone, 5 µg/ml insulin, and 500 µM methylisobutylxanthine. After 48 h (day 2), the cells were fed with high glucose DMEM, 10% fetal bovine serum containing 5 µg/ml insulin. After an additional 48 h (day 4), the cells were re-fed every 2 days with high glucose DMEM, 10% fetal bovine serum. All media were supplemented with 2 mM glutamine, 50 units of penicillin/ml, and 50 µg of streptomycin/ml. Differentiation was monitored by noting the accumulation of lipid droplets, which typically began by day 4 of differentiation. Cells were considered fully differentiated between days 8 and 12. CHO-K1 cells were cultured according to the protocol of the provider.

Uptake Experiments in 3T3-L1 Cells—Before the uptake experiments, 3T3-L1 cells were fed with serum-free DMEM with or without MG132 (10 µM) for 4 h and then incubated with or without insulin (1 µM) in uptake buffer, pH 7.4, for 30 min. Uptake experiments were carried out following the previously described protocol.³ The uptake buffer was 25 mM Tris/HEPES, pH 8.0, for MeAIB (7, 9) or HEPES/Tris, pH 7.4, for 2DG, and the buffer contained 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl₂, and 0.8 mM MgSO₄. The uptake experiment was performed in 3T3-L1 cells at 37 °C for 30 min with [¹⁴C]MeAIB or ¹⁴C-labeled 2DG as the substrate. The concentration of the radiolabeled substrate was 3.6 µM for MeAIB and 10 µM for 2DG. The culture medium was removed by aspiration, and the cells were washed once with the uptake buffer. 0.25 ml of uptake buffer containing radiolabeled substrate (MeAIB or 2DG) was added to the wells and incubated for 30 min at 37 °C. Uptake was terminated by aspirating the buffer and subsequently washing the cells twice with ice-cold fresh uptake buffer. The cells were then lysed with 0.25 ml of 1% SDS in 0.2 N NaOH, and the lysate was transferred to scintillation vials for quantification of radioactivity. Carrier-mediated uptake of the substrate was calculated by subtracting the uptake measured in the presence of an excess amount of unlabeled substrate (10 mM) from the uptake measured in the absence of unlabeled substrate.

Enhanced Green Fluorescent Protein (EGFP)-tagged ATA2 Expression in Mammalian Cells—CHO-K1 cells that transiently express ATA2 tagged with EGFP were established using the BD Living Colors pEGFP vector system from BD Biosciences Clontech (Palo Alto, CA), as described previously.³ Using the same cDNA construct (EGFP-ATA2), 3T3-L1 cells that stably express EGFP-tagged ATA2 were also established, as described previously.³ We have named this cell line EGFPATA2 3T3-L1 cells.

Co-expression of ATA2 and E3 Ubiquitin Ligase in Xenopus laevis Oocytes and Uptake Measurements—We followed the protocol for the preparation of cRNAs and the oocytes as described previously (24-27). Briefly, capped cRNAs from rat ATA2 (9), mouse Nedd4-2, and human c-Cbl cDNAs were synthesized using the mMESSAGE mMACHINE kit (Ambion, Austin, TX) as described previously. Mature oocytes (stage IV or V) from X. laevis were isolated by treatment with collagenase A (1.6 mg/ml), manually defolliculated, and maintained at 18 °C in modified Barth's medium supplemented with 10 mg/ml gentamycin. On the following day oocytes were injected with 25 ng of ATA2 cRNA and 25 ng of Nedd4-2 cRNA or c-Cbl cRNA. Water-injected oocytes served as controls. The oocytes were used for MeAIB uptake experiments 4 days after cRNA injection. Uptake of [¹⁴C]MeAIB into oocytes was measured in a 24-well microtiter plate as described previously (28). Briefly, 10 oocytes were incubated with the labeled substrate at room temperature for 60 min in the desired uptake buffer (100 mM NaC1, 2 mM KCl, 1 mM MgC1₂, and 1 mM CaC1₂ buffered with 10 mM Hepes/Tris, pH 8.0). Concentration of labeled amino acids was 7.2 µM. Uptake was terminated by washing the oocytes with ice-cold uptake medium four times. Each oocyte was then dissolved in 0.2 ml of 10% SDS, and radioactivity associated with the oocyte was determined by liquid scintillation spectrometry. Each experiment was repeated three times, and similar results were obtained each time.

Transient Co-expression of ATA2 and E3 Ubiquitin Ligase in CHO-K1 Cells—Plasmids encoding Nedd4 and Nedd4-2 in which conserved cysteine in the catalytic active site HECT domain was mutated to serine (CS mutant) (29) were generated by a site-directed mutagenesis kit (QuikChange XL, Stratagene, La Jolla, CA). We mutated the cysteine 854 or 822 to serine in the HECT domain of Nedd4 or Nedd4-2 and obtained the corresponding CS mutants, Nedd4 C854S or Nedd4-2 C822S. The cDNAs of EGFP-ATA2 and E3 ubiquitin ligase were co-transfected in CHO cells with Lipofectamine 2000 as described previously.³ Uptake experiments were performed by following the protocol in 3T3-L1 cells as described above using the 100 µM MeAIB and 20 min of incubation.

Cell Lysis and Immunoprecipitation—Cells were lysed with Triton X-100 lysis buffer containing 50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, protease inhibitor mixture (Complete, Roche Applied Science). An agarose-conjugated anti-GFP rat monoclonal antibody (Medical Biological Laboratories) was added to lysates and incubated at 4 °C for 1.5 h. The agarose-conjugated antibody was washed thoroughly (four times) with Triton X-100 lysis buffer and subjected to the Western blot analysis using the anti-ubiquitin or anti-GFP antibody. Biotinylation of cell surface proteins was performed by the method described by Rotmann et al. (30) for the study of the internalization of the cationic amino acid transporter with slight modifications.³ Briefly, the preadipocytes stably expressing EGFPATA2 protein were grown to confluence and differentiated into adipocytes in 10-cm dishes. After the experimental treatment, the cells were rinsed with ice-cold phosphate-buffered saline (PBS) containing 0.1 mM CaCl₂ and 1 mM MgCl₂ (PBS+) and incubated in the same solution supplemented with 0.5 mg/ml sulfosuccinimidobiotin (EZ-Link sulfo-NHS-SS-Biotin: Pierce) for 30 min at 4 °C. The cells were then rinsed with the quenching solution in the cell surface protein biotinylation and purification kit (Pierce) once and Tris-buffered saline twice to quench any unbound biotin. The cells were then lysed by the addition of 1 ml of radioimmunoprecipitation assay buffer (100 mM Tris/HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS) containing protease inhibitors (Complete EDTA-free; Roche Diagnostics) for 30 min at 4 °C. After removal of the cellular debris, protein concentrations of the lysates were determined using the Bradford method. 1 mg of the lysate proteins were batch-extracted overnight at 4 °C using avidin-coated agarose beads (immobilized NeutrAvidin, Pierce) and then released from the beads by incubation in the SDS-PAGE sample buffer (50 mM Tris/HCl, pH 6.8, 2% SDS, 100 mM dithiothreitol, 10% glycerol, 0.001% bromphenol blue, 5 min at 95 °C).

Western Blot Analysis—Cell lysates, immunoprecipitated proteins, or cell surface proteins were separated in 6-10% SDS-PAGE and then blotted onto polyvinylidene difluoride membranes (Millipore, Billerica, MA). The membranes were probed with the appropriate primary antibodies. The bound primary antibodies were detected with the corresponding horseradish peroxidase-conjugated secondary antibodies. Signal was visualized using ECL kit (Amersham Biosciences).

Stealth siRNA Treatment—We obtained two Stealth siRNA for mouse Nedd4-2 from Invitrogen. Each siRNA is a 25-bp duplex oligoribonucleotide with a sense strand corresponding to nucleotides 1755-1779 or 2336-2360 of the reported mouse Nedd4-2 coding sequence (GenBank^TM accession number BC039746 [GenBank] ). The sense sequences of Nedd4-2 siRNA 1755 and 2336 are 5'-AAACUCUCUGGAGUACGGAACAGCC-3' and 5'-UUCAGAUCCACUUGGUAUGUCUGCC-3', respectively. Nedd4-2-scrambled control-siRNA 1755 and 2336 with sense strands 5'-AAACAUCCUCGGUUGAGCAAAGGCC-3' and 5'-UUCCUGACUACACGUUAUGUGUGCC-3' are the control stealth siRNAs for Nedd4-2 siRNA 1755 and 2336, respectively. 3T3-L1 preadipocytes were transfected by 20 nM of the Nedd4-2 siRNA or the control siRNA in the antibiotic-free growth medium using Lipofectamine 2000 per the instructions of the manufacturer. After siRNA treatment (24 h), the medium containing the Nedd4-2 siRNA or the control siRNA was changed to fresh medium. 24 h after the medium change (i.e. 48 h after the initiation of RNAi treatment), the cells were used for MeAIB uptake experiments or immunoprecipitation as described above and in the figure legends.

Immunofluorescent Analysis and Confocal Laser Scanning Microscopy—3T3-L1 adipocytes were fixed with 4% paraformaldehyde for 15 min and permeabilized with 0.2% Triton X-100 in phosphate-buffered saline for 15 min. Coverslips were incubated with diluted Nedd4-2 antibody for 1 h and with diluted Alexa568-conjugated secondary antibodies in 2% skim milk, 0.1% Triton X-100, 0.02% SDS, phosphate-buffered saline for 30 min. Images were taken with upright confocal laser scanning microscope Carl Zeiss LSM5 PASCAL (Carl Zeiss, Oberkochen, Germany).

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Proteasome Inhibition Increased ATA2 Transport Activity by Increasing the Amount of ATA2 Protein in 3T3-L1 Adipocytes and Preadipocytes—To determine the effect of the proteasome inhibition on ATA2 transport activity, we treated 3T3-L1 adipocytes or preadipocytes with a proteasome inhibitor MG132 and then measured the uptake of MeAIB, a specific substrate for ATA2 into the cells (Fig. 1A). In adipocytes as well as preadipocytes, the treatment with MG132 for 4 h accelerated MeAIB uptake significantly. The effects of insulin and MG132 were additive. The uptake of 2DG, a specific substrate for the members of the facilitated glucose transporter family (GLUTs) did not show any change after MG132 treatment either with or without insulin (data not shown). We also used the 3T3-L1 cell line stably transfected with the EGFP-tagged ATA2 (EGFPATA2 3T3-L1 cells) to observe the changes of intracellular localization of ATA2. The establishment of this cell line has been described previously.³ In adipocytes as well as preadipocytes, the fluorescent signals associated with EGFP-ATA2 were markedly increased after treatment with MG132 (Fig. 1B). We compared the fluorescence signals under identical conditions in cells treated with or without MG132. We first optimized the experimental conditions in MG132-treated cells to avoid the saturation of signals and then applied identical conditions to nontreated cells. Strong signals were detected at the perinuclear site in MG132-treated cells. Under these conditions, the signals from nontreated cells were barely detectable. We also analyzed the steady-state levels of the ATA2 fusion protein by Western blot using anti-GFP antibody with whole cell lysates from EGFP-ATA2 3T3-L1 adipocytes and preadipocytes treated with or without MG132 (Fig. 1C). The band corresponding to 74 kDa (indicated with the arrow in Fig. 1C) was the intact EGFP-ATA2 protein as described previously,³ and the signal intensity of this band was increased by MG132 treatment in adipocytes as well as in preadipocytes. In addition to the band corresponding to the size of the intact, unmodified EGFPATA2, there were other protein bands with a range of higher molecular sizes whose intensities were also increased markedly in MG132-treated cells.

View larger version (32K): [in this window] [in a new window]   FIGURE 1. Proteasome inhibition increases ATA2 protein in 3T3-L1 cells. A, the proteasome inhibitor MG132 increases carrier-mediated MeAIB uptake both in 3T3-L1 adipocytes as well as preadipocytes. Values are the means ± S.E. from three determinations. B, proteasome inhibition increases the fluorescent signal from EGFP-ATA2 in 3T3-L1 adipocytes and preadipocytes stably expressed with EGFP-ATA2. Images were obtained with a confocal laser scanning microscope. Identical conditions were used to capture the images in cells treated with or without MG132 (10 µM for 4 h). As we applied the optimal conditions for the capture of the fluorescence signals in MG132-treated cells, the signals from the nontreated cells were barely detectable. Strong signals were detected at the perinuclear site in MG132-treated cells. Scale bar, 20 µm. The data are from a representative experiment, and similar results were obtained from two other experiments. C, proteasome inhibition increases the signals detectable with the anti-GFP antibody in the Western blot (IB) with the lysates of 3T3-L1 adipocytes and preadipocytes stably transfected with EGFP-ATA2. The cells were treated with or without MG132 (10 µM) for 4 h before the harvest. The data are from a representative experiment, and similar results were obtained from two other experiments.

View larger version (68K): [in this window] [in a new window]   FIGURE 2. Evidence for polyubiquitination of EGFP-ATA2 in 3T3-L1 cells. 3T3-L1 adipocytes stably transfected EGFP-ATA2 were treated with or without MG132 for 4 h, and the lysates were used for immunoprecipitation (IP) with the anti-GFP antibody. Immunoprecipitated proteins were separated in the SDS-PAGE and blotted (IB) with anti-ubiquitin (Ub) or GFP antibody. The data are from a representative experiment, and similar results were obtained from two other experiments.

Influence of Ubiquitin Ligase on ATA2 Transport Function upon Co-expression in Xenopus Oocytes—To determine the effect of ubiquitination on ATA2, we co-expressed ATA2 with either Nedd4-2 (a HECT domain E3) or c-Cbl (a RING domain E3) in Xenopus oocytes and then monitored the transport function of ATA2 by measuring the Na⁺-dependent uptake of MeAIB (Fig. 3). This co-expression system has been used by several investigators to determine the molecular identity of the ubiquitin ligase that interacts with any given target protein (31-33). Co-expression of Nedd4-2 with ATA2 down-regulated ATA2-mediated MeAIB uptake, whereas c-Cbl did not affect MeAIB uptake significantly.

View larger version (17K): [in this window] [in a new window]   FIGURE 3. Effect of co-injection of Nedd4-2 cRNA or c-Cbl cRNA on MeAIB uptake induced by ATA2 cRNA injection in X. laevis oocytes. Values are the means ± S.E. from the ten oocytes.

Effect of Knockdown of Nedd4-2 on the Activity and Ubiquitination of ATA2 in 3T3-L1 Cells—To evaluate the physiological relevance of endogenous Nedd4-2 in ubiquitination/internalization/degradation of ATA2, we knocked down the endogenous Nedd4-2 in 3T3-L1 preadipocytes by RNAi and then monitored the transport function of ATA2 by uptake measurements and the extent of ubiquitination of the EGFP-ATA2 fusion protein by Western blot (Figs. 5 and 6). We first confirmed the RNAi-induced down-regulation of Nedd4-2 protein by Western blot using cell lysates prepared from cells treated with two independent Nedd4-2-specific siRNAs or with the corresponding nonspecific scrambled siRNAs (Fig. 5A). Knockdown effect for Nedd4-2 siRNA 1755 or 2336 normalized with -tubulin was 86 and 88%. The down-regulation of Nedd4-2 by two independent siRNAs resulted in the significant increase in the transport function of ATA2 as evident from the increase in MeAIB uptake (Fig. 5B). Insulin treatment enhanced the extent of increase of MeAIB uptake induced by both Nedd4-2 siRNAs. With the proteins immunoprecipitated by the anti-GFP antibody from the lysates of cells treated with the Nedd4-2 siRNA 1755 or its scrambled control siRNA, we performed the Western blot analysis using the anti-ubiquitin antibody and observed the differences of the band pattern (Fig. 6A). Three bands with approximate sizes of 190, 215, and 240 kDa that were detectable with the anti-ubiquitin antibody in lysates from cells treated with nonspecific siRNA were decreased most in lysates from cells treated with Nedd4-2-specific siRNA (Fig. 6A, left, indicated with the arrowheads). Similar results were obtained when the blots were probed with anti-GFP antibody, although the signals were so weak that the long exposure time for ECL detection was needed (Fig. 6A, right). This difference of detectability with the anti-ubiquitin or anti-GFP antibody is due to the stoichiometry of EGFP-ATA2 and ubiquitin for polyubiquitination. We analyzed the ubiquitination of EGFP-ATA2 on the surface membrane in the cells treated with Nedd4-2 siRNA or its scrambled control after MG132 treatment (Fig. 6B). The Western blots of the cell surface membrane proteins with anti-GFP antibody showed that the intensities from protein bands with a range of higher molecular sizes were decreased by RNAi of Nedd4-2. The bands with the size of 190250 and 155170 kDa were decreased most.

View larger version (24K): [in this window] [in a new window]   FIGURE 4. Effect of Nedd4, Nedd4-2, or c-Cbl co-expression on MeAIB uptake induced by EGFP-ATA2 transfection in CHO cells. Values are the means ± S.E. from three determinations. wt, wild type.

View larger version (24K): [in this window] [in a new window]   FIGURE 5. Knockdown of Nedd4-2 by siRNA causes an increase of MeAIB uptake in 3T3-L1 preadipocytes. A, Western blot confirms the siRNA-mediated knockdown of Nedd4-2 protein in 3T3-L1 preadipocytes. Upper, the data are from a representative experiment, and similar results were obtained from two other experiments. Lower, relative Nedd4-2 protein abundance is shown. Values were normalized with -tubulin. Values are the means ± S.E. from three determinations. B, the down-regulation of Nedd4-2 by two independent siRNAs resulted in the significant increase in the transport function of ATA2 as evident from the increase in MeAIB uptake. Insulin treatment (1 µM for 30 min) enhanced the extent of increase of MeAIB uptake induced by both Nedd4-2 siRNAs. Values are the means ± S.E. from three determinations.

View larger version (29K): [in this window] [in a new window]   FIGURE 6. Participation of Nedd4-2 in polyubiquitination of ATA2 in 3T3-L1 cells. Knockdown of Nedd4-2 by siRNA decreased the densities of the bands for polyubiquitinated EGFP-ATA2 in 3T3-L1 preadipocytes (indicated with the arrow) in Western blots (IB) of the proteins immunoprecipitated (IP) from total lysates (A) and the cell surface proteins (B). The immunoblot of transferrin receptor (TfR) is shown as a loading control. The cells were treated with MG132 (10 µM) for 4 h before the harvest. The data are from a representative experiment, and similar results were obtained from two other experiments.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

View larger version (59K): [in this window] [in a new window]   FIGURE 7. Partial co-localization of EGFP-tagged ATA2 and Nedd4-2 on the plasma membrane in 3T3-L1 adipocytes. 3T3-L1 adipocytes stably transfected with EGFP-ATA2 were treated with MG132 and insulin as described under "Experimental Procedures." Fluorescent immunohistochemical analysis shows that Nedd4-2 is co-localized partially with EGFPATA2 on the plasma membrane but not in the perinuclear ATA2 storage sites. EGFP-ATA2 is shown in green, and Nedd4-2 is in red. The data are from a representative experiment, and similar results were obtained from two other experiments. Scale bar, 10 µm.

There are several steps in the ubiquitin-proteasome protein degradation pathway, and the conjugation of ubiquitin to a target protein is the initiation in the pathway. Three types of enzymatic activities are necessary to catalyze the conjugation of ubiquitin to a target protein; they are a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2), and an ubiquitin ligase (E3) (21, 35). There is only one isoform of E1 in eukaryotic cells but many different E2s and E3s work together, influencing the turnover rate and specificity of the degradation process. E3 binds to E2 as well as the target protein; thus, E3 plays an important role in the determination of substrate specificity in the ubiquitin-proteasome pathway. Two primary classes of E3s have been described. One is distinguished by a HECT domain (e.g. Nedd4 and Nedd4-2) and the other by a RING domain (e.g. c-Cbl) (21, 35, 36). To establish the molecular identity of the E3 that is specific for ATA2, we tested the interaction of three different E3s: Nedd4, Nedd4-2, and c-Cbl. These three E3s are thought to be involved in the endocytosis of membrane proteins via ubiquitination (35, 36). Recently, Boehmer et al. (37) reported that co-expression of Nedd4-2 with amino acid transporter SN1 (SLC38A3) down-regulated SN1-mediated amino acid transport in Xenopus oocytes, although details of the mechanism were not examined. Here we show that the co-expression of Nedd4-2, not c-Cbl, with ATA2 decreased the ATA2 activity in the oocytes significantly (Fig. 3). Moreover, to confirm that Nedd4-2 is indeed the E3 specific for ATA2, we performed the co-expression of ATA2 and Nedd4/Nedd4-2, their mutants in the HECT domain, or c-Cbl in CHO cells (Fig. 4). The HECT E3s participate in the catalytic reaction by forming a thioester bond with ubiquitin via conserved cysteine residue within the HECT domain during the transfer of ubiquitin from E2 to the target protein (21). The catalytically active wild type Nedd4-2 decreased ATA2 activity in EGFPATA2-expressing CHO cells, but the catalytically inactive mutant did not. Nedd4 showed only a minimal effect on ATA2 activity even though the protein was expressed at comparable levels as was Nedd4-2. Therefore, we conclude that Nedd4-2 is the principal E3 involved in degradation of ATA2. We confirmed the role of endogenous Nedd4-2 in the degradation of ATA2 via the ubiquitin-proteasome pathway using the RNAi technique (Figs. 5 and 6). RNAi of Nedd4-2 obviously increased ATA2 activity in 3T3-L1 cells. Interestingly, insulin treatment enhanced the extent of increase of MeAIB uptake induced by both Nedd4-2 siRNAs. Insulin stimulates the translocation of ATA2 to the plasma membrane (43)³; therefore, this result indicates the Nedd4-2 is involved in the sequestration of ATA2 from the membrane to the intracellular degradation site. We also show for the first time that Nedd4-2 localizes to a significant extent on the plasma membrane in 3T3-L1 adipocytes (Fig. 7). Nedd4-2 was not found to be co-localized with ATA2 at the perinuclear site, the intracellular ATA2 storage site. Instead, the co-localization was evident at the plasma membrane, suggesting that the principal site of ATA2 ubiquitination is on or near the plasma membrane. This is also the first evidence showing the co-localization of ATA2 and Nedd4-2 on the plasma membrane in the cells. Malik et al. (20) reported that Nedd4-2 is partially bound to the plasma membrane in A6 X. laevis distal nephron cell lines. Palmada et al. (38) also showed that Nedd4-2 is localized on or near the apical membrane as well as in the cytoplasm in human intestinal epithelial cells. Recently, Dunn et al. (39) reported that Rsp5, the yeast ortholog of Nedd4/Nedd4-2, binds membrane phosphoinositides and directs ubiquitination.

Ubiquitin coupling can be two different types; monoubiquitination and polyubiquitination. Monoubiquitination occurs when individual ubiquitin molecules are coupled to lysine residues on a target protein so that the final stoichiometry is one ubiquitin per lysine. In contrast, polyubiquitination involves the coupling of a chain of four or more ubiquitin molecules to one lysine residue on a target protein so that the final stoichiometry is four or more ubiquitin molecules per lysine. Monoubiquitinated proteins are degraded in lysosomes, whereas polyubiquitinated proteins are recognized and degraded by the 26 S proteasome (35, 36). Conjugation of an ubiquitin molecule to target proteins generally leads to a distinct SDS-PAGE mobility shift of relative molecular size with 7-8 kDa. The molecular size of EGFP-ATA2 in SDS-PAGE is 74 kDa as described above. Because we can predict the numbers of lysine in the intracellular domain of ATA2 as 12-15, EGFP-ATA2 proteins with the sizes of more than 180-195 kDa should be polyubiquitinated forms, excluding the possibility of multimonoubiquitination. EGFP-ATA2 proteins supposed to be ubiquitinated were detected both in the blot of the proteins immunoprecipitated from total lysates and the cell surface membrane proteins treated with Nedd4-2 siRNA or its scrambled control after MG132 treatment (Fig. 6). RNAi of Nedd4-2 decreased the 190-, 215-, and 240-kDa bands most in the proteins immunoprecipitated from the total lysates and 190250- and 155170-kDa bands in the cell surface membrane proteins. The 190240-kDa bands were common as decreased bands by Nedd4-2 siRNA in both the cell surface membrane proteins and the proteins immunoprecipitated from the total lysates. From the molecular size, the 190250-kDa bands are most likely to be polyubiquitinated EGFP-ATA2, as described above. Interestingly, the 90-kDa band was observed both in the proteins immunoprecipitated from total lysates and the cell surface membrane proteins. This band is likely to be EGFP-ATA2-conjugated with two ubiquitin molecules, implying multimonoubiquitinated EGFP-ATA2. This 90-kDa protein was neither so decreased by Nedd4-2 RNAi in the proteins immunoprecipitated from total lysates nor the cell surface proteins. In addition to the endocytic pathway from the plasma membrane, ubiquitinination of transmembrane proteins serves as a sorting signal of the proteins to direct their movement between different cellular compartments, for example, trans-Golgi network or endosomes (40). The ubiquitin ligase other than Nedd4-2 may be involved in the multimonoubiquitination of ATA2. The 190250-, 155170-, and 90-kDa proteins and the smearing band pattern were obvious only after MG132 treatment in the cell surface membrane proteins. This indicates that multimonoubiquitination of EGFP-ATA2 is not dominant in the cell surface membrane under a general condition and that it was increased by secondary effect after inhibition of proteasomal degradation of EGFP-ATA2 by MG132 caused the change of a dynamic equilibrium between intact EGFP-ATA2 and polyubiquitinated EGFP-ATA2.

Recently, Haynes et al. (41) reported that Rsp5, a yeast ortholog of Nedd4 and Nedd4-2, is involved in endoplasmic reticulum-associated degradation of a mutant form of the yeast vacuolar carboxypeptidase Y. As described above, insulin treatment enhanced the extent of increase of MeAIB uptake induced by Nedd4-2 RNAi. Insulin stimulates the translocation of ATA2 to the plasma membrane (43)³; therefore, this result indicates that the increased MeAIB uptake by Nedd4-2 RNAi is mainly attributed to the abolishment of polyubiquitination of ATA2 on the cell surface membrane, not to the inhibition of endoplasmic reticulum-associated degradation for ATA2. It is well established that growth hormone receptor is polyubiquitinated by an ubiquitin ligase (probably SOCS2) and internalized from the plasma membrane and degraded by the proteasome (42) in a similar way to ATA2.

The turnover rate of ATA2 appears to be high in 3T3-L1 adipocytes and preadipocytes because treatment of these cells with MG132 even for only 4 h resulted in more than a 2-fold increase of ATA2 activity in the cell surface. In contrast, the turnover rate of GLUT4, another insulin-responsive and important transporter in adipocytes, is comparatively slow (17) even though the insulin-mediated translocation of GLUT4 from intracellular sites to the plasma membrane is much faster than that of ATA2.³ GLUT4 trafficking is mainly regulated by insulin (34), whereas ATA2 trafficking as well as its expression is regulated by many factors including insulin and diabetes (3-5).³ The fast turnover of ATA2 suggested in the present study may reflect the ability of ATA2 expression and trafficking to respond differentially to a diversity of the regulatory factors.

	FOOTNOTES

 
^* This research was supported by PRESTO from Japan Science and Technology Agency (JST) and a WAKATE-A grant-in-aid from Ministry of Education, Culture, Sports, Science and Technology (MEXT) (to M. S.) and by WAKATE-B grant-in-aid from MEXT (to T. H.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom correspondence should be addressed: Mitsubishi Kagaku Institute of Life Sciences, 11 Minamiooya, Machida, Tokyo 194-8511, Japan. Tel.: 81-42-724-6259; Fax: 81-42-724-6316; E-mail: setou{at}nips.ac.jp.

² The abbreviations used are: MeAIB, -(methylamino)isobutyric acid; ATA, amino acid transporter A; 2DG, 2-deoxy-D-glucose; DMEM, Dulbecco's modified Eagle's medium; EGFP, enhanced green fluorescent protein; RNAi, RNA-mediated interference; E1, ubiquitin-activating enzyme; E2, ubiquitin-conjugating enzyme; E3, ubiquitin ligase; CHO, Chinese hamster ovary; siRNA, small interfering RNA; GLUT, glucose transporter.

³ Hatanaka, T., Hatanaka, Y., Tsuchida, J.-i., Ganapathy, V., and Setou, M. (October 18, 2006) J. Biol. Chem., 10.1074/jbc.M604534200.

	ACKNOWLEDGMENTS

 
We thank Dr. Vadivel Ganapathy in the Medical College of Georgia, Augusta, GA, for critically reading the manuscript. We are grateful to Drs. Tohru Tezuka and Tadashi Yamamoto in The Institute of Medical Science, The University of Tokyo and Dr. Keiji Tanaka at the Tokyo Metropolitan Institute of Medical Science for kindly providing human c-Cbl cDNA. We are also grateful to Dr. Olivier Staub in University of Lausanne, Lausanne, Switzerland for kindly providing the anti-Nedd4-2 antibody. We thank M. Kawanami and K. Ohtsu at the Mitsubishi Kagaku Institute of Life Sciences for technical assistance. We also thank Dr. T. Kahyo at Mitsubishi Kagaku Institute of Life Sciences for helpful discussions.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 

1. Christensen, H. N. (1989) Methods Enzymol. 173, 576-616[Medline] [Order article via Infotrieve]
2. Christensen, H. N., Oxender, D. L., Liang, M., and Vatz, K. A. (1965) J. Biol. Chem. 240, 3609-3616[Free Full Text]
3. Haussinger, D., Lang, F., and Kilberg, M. S. (1992) Mammalian Amino Acid Transport: Mechanisms and Control, pp. 113-130, Plenum Press, New York
4. Kilberg, M. S., Bracy, D. S., and Handlogten, M. E. (1986) Fed. Proc. 45, 2438-2441[Medline] [Order article via Infotrieve]
5. Shotwell, M. A., Kilberg, M. S., and Oxender, D. L. (1983) Biochim. Biophys. Acta 737, 267-284[Medline] [Order article via Infotrieve]
6. Hatanaka, T., Huang, W., Ling, R., Prasad, P. D., Sugawara, M., Leibach, F. H., and Ganapathy, V. (2001) Biochim. Biophys. Acta 1510, 10-17[Medline] [Order article via Infotrieve]
7. Hatanaka, T., Huang, W., Wang, H., Sugawara, M., Prasad, P. D., Leibach, F. H., and Ganapathy, V. (2000) Biochim. Biophys. Acta 1467, 1-6[Medline] [Order article via Infotrieve]
8. Reimer, R. J., Chaudhry, F. A., Gray, A. T., and Edwards, R. H. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 7715-7720[Abstract/Free Full Text]
9. Sugawara, M., Nakanishi, T., Fei, Y. J., Huang, W., Ganapathy, M. E., Leibach, F. H., and Ganapathy, V. (2000) J. Biol. Chem. 275, 16473-16477[Abstract/Free Full Text]
10. Sugawara, M., Nakanishi, T., Fei, Y. J., Martindale, R. G., Ganapathy, M. E., Leibach, F. H., and Ganapathy, V. (2000) Biochim. Biophys. Acta 1509, 7-13[Medline] [Order article via Infotrieve]
11. Varoqui, H., Zhu, H., Yao, D., Ming, H., and Erickson, J. D. (2000) J. Biol. Chem. 275, 4049-4054[Abstract/Free Full Text]
12. Wang, H., Huang, W., Sugawara, M., Devoe, L. D., Leibach, F. H., Prasad, P. D., and Ganapathy, V. (2000) Biochem. Biophys. Res. Commun. 273, 1175-1179[CrossRef][Medline] [Order article via Infotrieve]
13. Yao, D., Mackenzie, B., Ming, H., Varoqui, H., Zhu, H., Hediger, M. A., and Erickson, J. D. (2000) J. Biol. Chem. 275, 22790-22797[Abstract/Free Full Text]
14. Mackenzie, B., and Erickson, J. D. (2004) Pfluegers Arch. Eur. J. Physiol. 447, 784-795[CrossRef][Medline] [Order article via Infotrieve]
15. Hyde, R., Christie, G. R., Litherland, G. J., Hajduch, E., Taylor, P. M., and Hundal, H. S. (2001) Biochem. J. 355, 563-568[Medline] [Order article via Infotrieve]
16. Ritchie, J. W., Baird, F. E., Christie, G. R., Stewart, A., Low, S. Y., Hundal, H. S., and Taylor, P. M. (2001) Cell. Physiol. Biochem. 11, 259-270[CrossRef][Medline] [Order article via Infotrieve]
17. Sargeant, R. J., and Paquet, M. R. (1993) Biochem. J. 290, 913-919[Medline] [Order article via Infotrieve]
18. Malik, B., Schlanger, L., Al-Khalili, O., Bao, H. F., Yue, G., Price, S. R., Mitch, W. E., and Eaton, D. C. (2001) J. Biol. Chem. 276, 12903-12910[Abstract/Free Full Text]
19. Xia, X., Roundtree, M., Merikhi, A., Lu, X., Shentu, S., and Lesage, G. (2004) J. Biol. Chem. 279, 44931-44937[Abstract/Free Full Text]
20. Malik, B., Yue, Q., Yue, G., Chen, X. J., Price, S. R., Mitch, W. E., and Eaton. D. C. (2005) Am. J. Physiol. 289, F107-F116
21. Hershko, A., and Ciechanover, A. (1998) Annu. Rev. Biochem. 67, 425-479[CrossRef][Medline] [Order article via Infotrieve]
22. Bose, A., Cherniack, A. D., Langille, S. E., Nicoloro, S. M., Buxton, J. M., Park, J. G., Chawla, A., and Czech, M. P. (2001) Mol. Cell. Biol. 21, 5262-5275[Abstract/Free Full Text]
23. Harrison, S. A., Buxton, J. M., Clancy, B. M., and Czech, M. P. (1990) J. Biol. Chem. 265, 20106-20116[Abstract/Free Full Text]
24. Hatanaka, T., Nakanishi, T., Huang, W., Leibach, F. H., Prasad, P. D., Ganapathy, V., and Ganapathy, M. E. (2001) J. Clin. Investig. 107, 1035-1043[Medline] [Order article via Infotrieve]
25. Nakanishi, T., Hatanaka, T., Huang, W., Prasad, P. D., Leibach, F. H., Ganapathy, M. E., and Ganapathy, V. (2001) J. Physiol. (Lond.) 532, 297-304[Abstract/Free Full Text]
26. Hatanaka, T., Huang, W., Nakanishi, T., Bridges, C. C., Smith, S. B., Prasad, P. D., Ganapathy, M. E., and Ganapathy, V. (2002) Biochem. Biophys. Res. Commun. 291, 291-295[CrossRef][Medline] [Order article via Infotrieve]
27. Hatanaka, T., Haramura, M., Fei, Y. J., Miyauchi, S., Bridges, C. C., Ganapathy, P. S., Smith, S. B., Ganapathy, V., and Ganapathy, M. E. (2004) J. Pharmacol. Exp. Ther. 308, 1138-1147[Abstract/Free Full Text]
28. Fei, Y. J., Prasad, P. D., Leibach, F. H., and Ganapathy, V. (1995) Biochemistry 34, 8744-8751[CrossRef][Medline] [Order article via Infotrieve]
29. Magnifico, A., Ettenberg, S., Yang, C., Mariano, J., Tiwari, S., Fang, S., Lipkowitz, S., and Weissman, A. M. (2003) J. Biol. Chem. 278, 43169-43177[Abstract/Free Full Text]
30. Rotmann, A., Strand, D., Martine, U., and Closs, E. I. (2004) J. Biol. Chem. 279, 54185-54192[Abstract/Free Full Text]
31. Debonneville, C., Flores, S. Y., Kamynina, E., Plant, P. J., Tauxe, C., Thomas, M. A., Munster, C., Chraibi, A., Pratt, J. H., Horisberger, J. D., Pearce, D., Loffing, J., and Staub, O. (2001) EMBO J. 20, 7052-7059[CrossRef][Medline] [Order article via Infotrieve]
32. Konstas, A. A., Shearwin-Whyatt, L. M., Fotia, A. B., Degger, B., Riccardi, D., Cook, D. I., Korbmacher, C., and Kumar, S. (2002) J. Biol. Chem. 277, 29406-29416[Abstract/Free Full Text]
33. Boehmer, C., Henke, G., Schniepp, R., Palmada, M., Rothstein, J. D., Broer, S., and Lang, F. (2003) J. Neurochem. 86, 1181-1188[Medline] [Order article via Infotrieve]
34. Bryant, N. J., Govers, R., and James, D. E. (2002) Nat. Rev. Mol. Cell Biol. 3, 267-277[CrossRef][Medline] [Order article via Infotrieve]
35. d'Azzo, A., Bongiovanni, A., and Nastasi, T. (2005) Traffic 6, 429-441[CrossRef][Medline] [Order article via Infotrieve]
36. Dupre, S., Urban-Grimal, D., and Haguenauer-Tsapis, R. (2004) Biochim. Biophys. Acta 1695, 89-111[Medline] [Order article via Infotrieve]
37. Boehmer, C., Okur, F., Setiawan, I., Broer, S., and Lang, F. (2003) Biochem. Biophys. Res. Commun. 306, 156-162[CrossRef][Medline] [Order article via Infotrieve]
38. Palmada, M., Dieter, M., Speil, A., Bohmer, C., Mack, A. F., Wagner, H. J., Klingel, K., Kandolf, R., Murer, H., Biber, J., Closs, E. I., and Lang, F. (2004) Am. J. Physiol. 287, G143-G150
39. Dunn, R., Klos, D. A., Adler, A. S., and Hicke, L. (2004) J. Cell Biol. 165, 135-144[Abstract/Free Full Text]
40. Hicke, L., and Dunn, R. (2003) Annu. Rev. Cell Dev. Biol. 19, 141-172[CrossRef][Medline] [Order article via Infotrieve]
41. Haynes, C. M., Caldwell, S., and Cooper, A. A. (2002) J. Cell Biol. 158, 91-101[Abstract/Free Full Text]
42. Flores-Morales, A., Greenhalgh, C. J., Norstedt, G., and Rico-Bautista, E. (2006) Mol. Endocrinol. 20, 241-253[Abstract/Free Full Text]
43. Hyde, R., Peyrollier, K., and Hundal, H. S. (2002) J. Biol. Chem. 277, 13628-13634[Abstract/Free Full Text]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				R. Hyde, E. L. Cwiklinski, K. MacAulay, P. M. Taylor, and H. S. Hundal Distinct Sensor Pathways in the Hierarchical Control of SNAT2, a Putative Amino Acid Transceptor, by Amino Acid Availability J. Biol. Chem., July 6, 2007; 282(27): 19788 - 19798. [Abstract] [Full Text] [PDF]

				M. Miranda and A. Sorkin Regulation of Receptors and Transporters by Ubiquitination: New Insights into Surprisingly Similar Mechanisms Mol. Interv., June 1, 2007; 7(3): 157 - 167. [Abstract] [Full Text] [PDF]

				T. Hatanaka, Y. Hatanaka, J.-i. Tsuchida, V. Ganapathy, and M. Setou Amino Acid Transporter ATA2 Is Stored at the trans-Golgi Network and Released by Insulin Stimulus in Adipocytes J. Biol. Chem., December 22, 2006; 281(51): 39273 - 39284. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 281/47/35922    most recent M606577200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hatanaka, T. Articles by Setou, M.